Suppr超能文献

SIRT5 和 p53 蛋白在结肠癌细胞对化疗药物 5-氟尿嘧啶敏感性中的作用。

The role of SIRT5 and p53 proteins in the sensitivity of colon cancer cells to chemotherapeutic agent 5-Fluorouracil.

机构信息

Department of Biochemistry, Faculty of Pharmacy, University of Ankara, Do Gol Street, Tandogan, Ankara, Turkey.

出版信息

Mol Biol Rep. 2021 Jul;48(7):5485-5495. doi: 10.1007/s11033-021-06558-9. Epub 2021 Jul 19.

Abstract

BACKGROUND

In the treatment of colorectal cancer, it is important to develop drug combinations that will increase the effectiveness of chemotherapy and to determine the molecular targets of the drugs. Therefore, combined therapies that can increase the sensitivity of 5-Fluorouracil (5-FU) and the molecular pathways involved in this process are important in the treatment of the disease. Here we examined the SIRT5 (Resveratrol and Suramin) and p53 (Nutlin3a) modulators alone or in combination with 5-FU on the proliferation of colon cancer cells and effect of 5-FU on the SIRT5 and FOXO3a protein expressions whether p53 dependent or independent manner. METHODS AND RESULTS: According to our MTT assay results, Resveratrol (RSV), Nutlin3a and Suramin was found to be more effective in HCT-116 p53+/+ cells and these differences were evaluated together with the effect of 5-FU on the SIRT5, FOXO3a and Bim protein expressions in HCT-116 p53 +/+ and HCT-116 p53 -/- cells. SIRT5 is known to deacetylate FOXO3a which plays roles in the induction of apoptosis via Bim protein. Our western blot experiment results showed that while Suramin decreased SIRT5 and RSV decreased FOXO3a protein expressions significantly in HCT-116 p53 -/- cells, 5-FU decreased significantly SIRT5 and FOXO3a protein expressions in a p53 independent manner.

CONCLUSIONS

In this study, the effect of 5-FU on SIRT5 and FOXO 3a proteins was determined for the first time in HCT-116 p53 +/+ and HCT-116 p53 -/- cells. These results may help the discovery of new markers in colon cancer treatment.

摘要

背景

在结直肠癌的治疗中,开发能够提高化疗效果的药物组合并确定药物的分子靶点非常重要。因此,增加 5-氟尿嘧啶(5-FU)敏感性和涉及该过程的分子途径的联合疗法对于疾病的治疗非常重要。在这里,我们研究了 SIRT5(白藜芦醇和苏拉明)和 p53(Nutlin3a)调节剂单独或与 5-FU 联合对结肠癌细胞增殖的影响,以及 5-FU 是否以依赖或不依赖 p53 的方式影响 SIRT5 和 FOXO3a 蛋白表达。

方法和结果

根据我们的 MTT 检测结果,发现白藜芦醇(RSV)、Nutlin3a 和苏拉明在 HCT-116 p53+/+细胞中更有效,这些差异与 5-FU 对 HCT-116 p53+/+和 HCT-116 p53-/-细胞中 SIRT5、FOXO3a 和 Bim 蛋白表达的影响一起进行了评估。SIRT5 已知去乙酰化 FOXO3a,后者通过 Bim 蛋白在诱导细胞凋亡中发挥作用。我们的 Western blot 实验结果表明,苏拉明在 HCT-116 p53-/-细胞中显著降低 SIRT5 和 RSV 降低 FOXO3a 蛋白表达,而 5-FU 以不依赖 p53 的方式显著降低 SIRT5 和 FOXO3a 蛋白表达。

结论

本研究首次在 HCT-116 p53+/+和 HCT-116 p53-/-细胞中确定了 5-FU 对 SIRT5 和 FOXO3a 蛋白的作用。这些结果可能有助于发现结直肠癌治疗中的新标志物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验